SCHEMBL12434018

SCHEMBL12434018

CCC[C@H](OC(=O)NCc1ccccc1-c1ccccc1C(=O)NCc1ccc(F)cc1F)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 14/20 0.64
KCNK3 O14649 1/20 0.56
KCNK5 O95279 1/20 0.56
KCNK17 Q96T54 1/20 0.56
KCNK9 Q9NPC2 1/20 0.56
KCNA3 P22001 1/20 0.47
AKR1B1 P15121 1/20 0.41
PDE10A Q9Y233 1/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
LMNA P02545 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13789489 0.92 KCNA5 (0.54) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434016 0.87 KCNA5 (0.68) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434044 0.80 KCNA5 (0.74) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL2208881 0.79 KCNA5 (0.70) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434017 0.79 KCNA5 (0.60) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789493 0.79 KCNA5 (0.60) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL2208671 0.78 KCNA5 (1.00) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434042 0.78 KCNA5 (0.71) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434019 0.77 KCNA5 (0.78) KCNA5KCNK3KCNA3LMNATAS1R3
SCHEMBL12434045 0.77 KCNA5 (0.78) KCNA5KCNK3KCNK5KCNK17KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885KCNK3 346/4885KCNK5 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.